GlassScriptPhysician profile
Nathan R Bertoldo
NPI 1851731558
$3,889.08
in general payments reported to CMS, 2019-2025
24 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $81.50 · 2021: $1,345 · 2022: $378 · 2023: $534 · 2024: $269 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Travel and Lodging: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.54 |
| Travel and Lodging | $742.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,107.83 | 2021 | |
| Coloplast Corp | $997.76 | 2022-2025 | |
| Abbvie INC. | $409.27 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Merz North America, INC. | $277.73 | 2021-2024 | Xeomin |
| Hologic Sales and Service, LLC | $168.57 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Caldera Medical, INC | $141.59 | 2023 | Desara |
| Organon LLC | $114.62 | 2021-2024 | Nexplanon, Jada System, Nuvaring |
| Axonics, INC. | $101.72 | 2024 | Bulkamid |
| Becton, Dickinson and Company | $77.63 | 2022-2024 | Bd Onclarity |
| Biogen, INC. | $65.06 | 2025 | Zurzuvae |
| Medtronic, INC. | $64.34 | 2022 | |
| Merck Sharp & Dohme LLC | $56.48 | 2019-2020 | |
| Exeltis, USA INC. | $55.83 | 2022-2025 | Slynd |
| Evofem Biosciences, INC. | $48.04 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $45.31 | 2024-2025 | Myfembree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $33.21 | 2022-2023 | |
| Astellas Pharma US INC | $28.35 | 2024 | Veozah |
| Medicem INC. | $19.54 | 2022 | |
| Pfizer INC. | $14.54 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.61 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $13.17 | 2024 | Bd Onclarity |
| Myovant Sciences INC. | $12.50 | 2021 | |
| Glaxosmithkline, LLC. | $11.51 | 2021 | |
| Si-Bone, INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Bertoldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.